Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-α2b versus rIFN-γ versus ISCADOR M® versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis - Kleeberg, Ulrich R.; Schadendorf, Dirk (European journal of cancer, 2004)
Available online 27 November 2003